RxDoctor Payments Data

Shinto Koshy, MD

Physical Medicine & Rehabilitation · Placentia, CANPI 1780816314

Payments from drug & device makers

$3,519in general payments, 2019–2025

Across 159 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$2K
  • Boston Scientific$274
  • Abbott$269
  • Stryker$109
  • Globus Medical$108
  • Medtronic$89
  • plus $479 from 15 others
$16in research payments, 2019–2025

Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$16

What the payments were for

  • Travel & lodging$351%
  • Food & beverage$3,48499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,519 in reported general payments places this provider in the 85th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$262,358
Medicare patients
337
Services billed
3,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen254$27,546
Fentanyl73$18,853
Xtampza ErOxycodone Myristate13$11,404
MovantikNaloxegol Oxalate25$9,890
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen373$9,170
Lidocaine47$5,551
Oxycodone Hcl218$4,170
Gabapentin262$3,849
Morphine Sulfate ErMorphine Sulfate106$3,238
Hydromorphone Hcl40$2,445
Naloxone Hcl34$2,006
Pregabalin62$1,856
Acetaminophen-CodeineAcetaminophen With Codeine51$1,501
Methocarbamol70$1,480
Tramadol Hcl76$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$68$11,40413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Placentia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →